Liver Transplant Rejection – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Liver Transplant Rejection – Drugs In Development, 2024 report and make more profitable business decisions.
Liver transplantation is the conventional therapy used in various liver diseases. The liver has the unique ability to regenerate or regrow. Liver transplantation replaces an injured or diseased liver with a healthy one; an entire liver or just a section may be transplanted. Following a transplant, the immune system may consider the transplanted liver as foreign and may work against it. Patients may develop complications and ultimately reject the new organ. Therefore, immunosuppressive drugs are administered simultaneously. These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses, thus blocking organ rejection and facilitating a successful transplant.
The Liver Transplant Rejection drugs in development market research report provide comprehensive information on the therapeutics under development for Liver Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Transplant Rejection and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Liver Transplant Rejection | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 16 molecules, with 10 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Liver Transplant Rejection therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Liver Transplant Rejection pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Liver Transplant Rejection treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Alexion Pharmaceuticals IncAstellas Pharma Inc
Dompe Farmaceutici SpA
Eledon Pharmaceuticals Inc
Genexine Inc
Helmholtz Center Munich German Research Center for Health and Environment GmbH
Huazhong University of Science & Technology
ITB-Med AB
Junten Bio Co Ltd
King's College London
Nanjing Medical University
Quell Therapeutics Ltd
University of Pittsburgh
Veloxis Pharmaceuticals AS
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Liver Transplant Rejection reports